It’s fascinating this is the least discussed major section last night and this morning.
Anyway, I’ll repeat that my bet is on Merck and Oncovir, but my feelings wouldn’t be hurt if it was someone other than Merck.
What’s remarkable is that the completed contract is limited to one synergistic company and one booster manufacturing company.
That sounds like, to me, the multiple companies NWBO was negotiating with were set aside for a company more interested in exclusivity.
Market Data 
Markets 
